Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel

Summary Objective To investigate the correlations of three P2Y12 receptor (P2Y12R) gene polymorphisms (rs7428575 T>G, rs2046934 C>T, and rs3732759 A>G) with susceptibility to coronary artery disease ( CHD ) and clinical efficacy of clopidogrel treatment for CHD . Methods From May 2014 to May 2015, 178 CHD patients (the case group) and 182 healthy controls (the control group) were selected from our hospital. The platelet‐rich plasma ( PRP ) turbidimetry was used to measure the rate of adenosine diphosphate ( ADP )‐induced platelet aggregation before and after clopidogrel treatment. Clopidogrel‐sensitive group was defined as a 10% or greater decrease in the rate of platelet aggregation after 10 days of clopidogrel treatment, while clopidogrel‐resistant group was defined as a <10% decrease. Genotyping was performed by denaturing high‐performance liquid chromatography ( DHPLC ). A haplotype analysis of P2Y12R gene polymorphisms was performed using SHE sis software. Results There were significant differences in genotype and allele frequencies of rs2046934 C>T and rs3732759 A>G between the case and control groups (all P< .05). Haplotypes GTA and TTA were negatively associated with CHD risk (both P <.05), but haplotype TCA was positively associated with CHD risk ( P =.005). CHD patients in the clopidogrel‐sensitive group had higher frequencies of TT genotype of rs2046934 C>T and lower frequencies of GG genotype of rs3732759 A>G than those in the clopidogrel‐resistant group (both P <.05). Conclusions P2Y12R gene rs2046934 C>T and rs3732759 A>G polymorphisms might be associated with the risk of CHD and the efficacy of clopidogrel treatment for CHD .